Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

Roche may be a relative latecomer to the cell therapy category, but it's sparing no expense to build a position within it.

As a first-line therapy, DS-1062/Keytruda had an ORR of 62%, compared to 50% with triple therapy with chemo, with a disease control rate (DCR) or 100% and 90%, respectively. In the second-line ...